Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

LONDON/COPENHAGEN, Feb 5 (Reuters) - Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors ...

As a pioneer in diabetes care, Novo has been in the business for over 85 years and claims 34% of the $80 billion-plus diabetes treatment market and roughly half of the more than $15 billion ...

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter ... But Novo said Wednesday it expects slower growth in 2025 compared to the prior year. The 2024 outlook estimated growth between ...

The target was broadly in line with investor expectations, though, who predicted sales growth slightly below 20% in 2025. Ozempic and Wegovy helped Novo Nordisk increase their annual sales by $15 ...

Novo Nordisk forecast slower sales growth for 2025 of between 16% to 24 ... work by mimicking a hormone called glucagon-like peptide-1, which suppresses appetite. Investors have now been eagerly ...